@article {Fijene246698, author = {Laur{\'e} M Fijen and Aldo Grefhorst and Johannes H M Levels and Danny M Cohn}, title = {Severe acquired hypertriglyceridemia following COVID-19}, volume = {14}, number = {11}, elocation-id = {e246698}, year = {2021}, doi = {10.1136/bcr-2021-246698}, publisher = {BMJ Specialist Journals}, abstract = {Severe hypertriglyceridemia is a major risk factor for acute pancreatitis. In exceptional cases, it is caused by plasma components inhibiting lipoprotein lipase activity. This phenomenon is predominantly associated with autoimmune diseases. Here, we report a case of severe hypertriglyceridemia due to a transient reduction in lipoprotein lipase activity following an episode of COVID-19 in an otherwise healthy 45-year-old woman. The lipoprotein lipase activity of the patient was markedly reduced compared with a healthy control and did recover to 20\% of the healthy control{\textquoteright}s lipoprotein lipase activity 5 months after the COVID-19 episode. Mixing tests substantiated reduced lipolytic capacity in the presence of the patient{\textquoteright}s plasma at presentation compared with a homozygous lipoprotein lipase-deficient control, which was no longer present at follow-up. Western blotting confirmed that the quantity of lipoprotein lipase was not aberrant. Fibrate treatment and a strict hypolipidemic diet improved the patient{\textquoteright}s symptoms and triglyceride levels.}, URL = {https://casereports.bmj.com/content/14/11/e246698}, eprint = {https://casereports.bmj.com/content/14/11/e246698.full.pdf}, journal = {BMJ Case Reports CP} }